Intellia Therapeutics

Intellia Therapeutics specializes in gene editing to develop novel therapeutics for various areas, including immuno-oncology, autoimmune, and genetic diseases. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 enzymes. 

The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, it was working on 3 internal drug programs and four collaborative programs. As of March 2024, one program was in the late clinical stage, one program was in the early clinical stage, and five were in the research and preclinical stage. The company considers its lipid nanoparticle delivery system to be a key strength in minimizing genotoxicity risk and random insertion.

Intellia acquired biotechnology company Rewrite Therapeutics for USD 45 million in February 2022 to leverage its gene editing and DNA-writing technologies. Intellia would also pay up to USD 155 million in additional milestone payments.

Key customers and partnerships

Intellia has partnered with a number of biotech and pharma companies, including: 1) Big pharma Novartis (January 2015), to research and co-develop CRISPR/Cas9-edited therapies to develop an ex-vivo treatment for sickle-cell disease and a number of undisclosed programs 2) Kyverna Therapeutics (January 2022), for the development of a next-generation CD19 CAR T-cell therapy for autoimmune diseases 3) ONK Therapeutics (February 2022), to develop engineered natural killer (NK) cell therapies for cancer treatment. 

In October 2023, the company expanded its research collaboration with Regeneron Pharmaceuticals (entered in April 2020) to develop gene-editing therapies for neurological and muscular diseases.

Funding and financials

Founded by Caribou Biosciences and Atlas Ventures in November 2014, Intellia has been listed on Nasdaq since May 2016. In November 2022 , the company raised USD 300 million via an underwritten public offering—it did not disclose the purpose of the financing. For 2022, the company reported a revenue of ~USD 52  million, earned through collaborations.